These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 16831950

  • 1. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.
    Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR.
    Ann N Y Acad Sci; 2006 Apr; 1068():543-56. PubMed ID: 16831950
    [Abstract] [Full Text] [Related]

  • 2. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease.
    Bernstein M, Irwin S, Greenberg GR.
    Am J Gastroenterol; 2005 Sep; 100(9):2031-5. PubMed ID: 16128948
    [Abstract] [Full Text] [Related]

  • 3. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U, Teichmann J, Müller-Ladner U, Strunk J.
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [Abstract] [Full Text] [Related]

  • 4. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.
    Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F.
    J Bone Miner Res; 1995 Feb; 10(2):250-6. PubMed ID: 7754804
    [Abstract] [Full Text] [Related]

  • 5. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 6. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M.
    Ann N Y Acad Sci; 2006 Jun 10; 1069():420-7. PubMed ID: 16855169
    [Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor-alpha haplotype is strongly associated with bone mineral density in patients with Crohn's disease.
    Lee N, Fowler E, Mason S, Lincoln D, Taaffe DR, Radford-Smith G.
    J Gastroenterol Hepatol; 2007 Jun 10; 22(6):913-9. PubMed ID: 17565648
    [Abstract] [Full Text] [Related]

  • 8. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
    Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, Han KH, Breedveld FC, Dijkmans BA, Allaart CF, Lems WF.
    Ann Rheum Dis; 2008 Jun 10; 67(6):823-8. PubMed ID: 17644545
    [Abstract] [Full Text] [Related]

  • 9. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K, Gossec L, Kolta S, Dougados M, Roux C.
    J Rheumatol; 2008 May 10; 35(5):855-61. PubMed ID: 18381782
    [Abstract] [Full Text] [Related]

  • 10. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep 10; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 11. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.
    Veerappan SG, O'Morain CA, Daly JS, Ryan BM.
    Aliment Pharmacol Ther; 2011 Jun 10; 33(12):1261-72. PubMed ID: 21521250
    [Abstract] [Full Text] [Related]

  • 12. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
    Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, Schoon E.
    Aliment Pharmacol Ther; 2004 Oct 15; 20(8):851-7. PubMed ID: 15479356
    [Abstract] [Full Text] [Related]

  • 13. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
    Ainsworth MA, Bendtzen K, Brynskov J.
    Am J Gastroenterol; 2008 Apr 15; 103(4):944-8. PubMed ID: 18028512
    [Abstract] [Full Text] [Related]

  • 14. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.
    Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P.
    Arthritis Res Ther; 2007 Apr 15; 9(3):R61. PubMed ID: 17597527
    [Abstract] [Full Text] [Related]

  • 15. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar 15; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 16. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy.
    Cino M, Greenberg GR.
    Am J Gastroenterol; 2002 Apr 15; 97(4):915-21. PubMed ID: 12003427
    [Abstract] [Full Text] [Related]

  • 17. Negative impact of Crohn's disease on bone mineral mass.
    Thodis E, Rossos P, Habal F, Oreopoulos D.
    J Musculoskelet Neuronal Interact; 2003 Sep 15; 3(3):246-50. PubMed ID: 15758348
    [Abstract] [Full Text] [Related]

  • 18. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
    Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP.
    Clin Immunol; 2006 Jan 15; 118(1):11-9. PubMed ID: 16125467
    [Abstract] [Full Text] [Related]

  • 19. Osteopenia in Puerto Ricans with Crohn's disease.
    Chinea B, Rosa A, Oharriz JJ, Ramírez M, Haddock L, Pérez C, Torres EA.
    P R Health Sci J; 2000 Dec 15; 19(4):329-33. PubMed ID: 11293884
    [Abstract] [Full Text] [Related]

  • 20. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM, Elstein D, Hrebícek M, Zimran A.
    Clin Ther; 2007 Aug 15; 29(8):1645-54. PubMed ID: 17919546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.